PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tutor Perini (TPC) Tops Q3 EPS by 92c; Offers Guidance
- CAI International (CAI) Misses Q3 EPS by 11c ; Offers Guidance
- Kimball Electronics (KE) Misses Q1 EPS by 13c, Beats on Revenue; Offers FY27 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
